^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    NQO1 mutation

    i
    Other names: NQO1, NAD(P)H Quinone Dehydrogenase 1, DTD, QR1, Diaphorase (NADH/NADPH) (Cytochrome B-5 Reductase), NAD(P)H Dehydrogenase [Quinone] 1, NAD(P)H Dehydrogenase, Quinone 1, NAD(P)H:Quinone Oxidoreductase 1, Phylloquinone Reductase, Menadione Reductase, Quinone Reductase 1, DT-Diaphorase, Azoreductase, NMOR1, DHQU, DIA4, NAD(P)H:Quinone Acceptor Oxidoreductase Type 1, NAD(P)H:Menadione Oxidoreductase 1, NAD(P)H:Quinone Oxireductase, Dioxin-Inducible 1, Diaphorase-4, NMORI
    Entrez ID:
    1728
    Related biomarkers:
    Expression
    over2years
    DNMT3A R882H mutation promotes acute leukemic cell survival by regulating glycolysis through the NRF2/NQO1 axis. (PubMed, Cell Signal)
    Taken together, these results suggest a novel mechanism by which a DNMT3A R882H mutation promotes glycolysis via activation of NRF2/NQO1 pathway. A parallel glycolysis inhibition adds to the anticancer effects of daunorubicin which might lead to a novel therapeutic approach for the treatment of AML patients carrying a DNMT3A R882H mutation.
    Journal
    |
    DNMT3A (DNA methyltransferase 1) • NQO1 (NAD(P)H dehydrogenase, quinone 1)
    |
    DNMT3A mutation • NFE2L2 mutation • DNMT3A R882H • DNMT3A R882 • NQO1 mutation
    |
    daunorubicin